Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 |
September 13, 2017
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Suzanne Hayes
Re: | Galapagos NV |
Form 20-F |
Filed March 23, 2017 |
File No. 001-37384 |
Dear Ms. Hayes:
This letter is being submitted on behalf of Galapagos NV (the Company) in response to the comments of the staff of the Division of Corporation Finance (the Staff) of the U.S. Securities and Exchange Commission (the Commission) with respect to the Companys Form 20-F filed on March 23, 2017 (the 2016 Annual Report), as set forth in your letter dated September 5, 2017 addressed to Mr. Bart Filius, Chief Financial Officer of the Company (the Comment Letter).
For reference purposes, the text of the Comment Letter has been reproduced herein with responses below each numbered comment. For your convenience, we have italicized the reproduced Staff comments from the Comment Letter.
Intellectual Property, page 62
1. | We refer to your proposed disclosure in response to comment 1, and note that two of your families of issued patents relating to your target discovery platform have upcoming expiration dates in 2019 and 2020, respectively. In future filings, please also discuss whether you expect the expiration of these patents to have a material effect on your business. |
RESPONSE: The Company respectfully acknowledges the Staffs comment and will revise its disclosure concerning its families of issued patents relating to its target discovery platform as follows:
September 13, 2017
Page 2
We do not believe that the expiration of these patents will materially affect our business, because they will not impact our patent coverage for our current clinical programs. The Company intends to reflect this change in its Annual Report for the fiscal year ending December 31, 2017, and in all future filings by the Company under the Securities Exchange Act of 1934, as amended, where such disclosure is applicable.
* * *
If you should have any questions concerning the enclosed matters, please contact the undersigned at (617) 570-1933.
Sincerely, |
/s/ Michael H. Bison |
Michael Bison |
Enclosures
cc: | Onno van de Stolpe, Chief Executive Officer, Galapagos NV |
Bart Filius, Chief Financial Officer, Galapagos NV |
Mitchell S. Bloom, Goodwin Procter LLP |
Qing Nian, Goodwin Procter LLP |